Europeiska unionen - svenska - EMA (European Medicines Agency)

argenx - efgartigimod alfa - myasthenia gravis - immunsuppressiva - vyvgart is indicated as an add on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gmg) who are anti acetylcholine receptor (achr) antibody positive.

Europeiska unionen - svenska - EMA (European Medicines Agency)

alexion europe sas - ravulizumab - hemoglobinuri, paroxysmal - selektiva immunsuppressiva medel - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

Europeiska unionen - svenska - EMA (European Medicines Agency)

paion deutschland gmbh - remimazolam besilate - bevisad sedation - neuroleptika - remimazolam is indicated in adults for procedural sedation. remimazolam 50 mg is indicated in adults for intravenous induction and maintenance of general anaesthesia.

Europeiska unionen - svenska - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - graftförkastning - immunsuppressiva - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

ebb medical ab - tiopentalnatrium - pulver till injektionsvätska, lösning - tiopentalnatrium 1 g aktiv substans - tiopental

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

ebb medical ab - tiopentalnatrium - pulver till injektionsvätska, lösning - tiopentalnatrium 1 g aktiv substans - tiopental

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

abboxia ab - tiopentalnatrium - pulver till injektionsvätska, lösning - tiopentalnatrium 1 g aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

teva b.v. - lidokain; prilokain - kräm - 25 mg/g + 25 mg/g - makrogolglycerolhydroxistearat hjälpämne; lidokain 25 mg aktiv substans; prilokain 25 mg aktiv substans - kombinationer

Europeiska unionen - svenska - EMA (European Medicines Agency)

neuraxpharm pharmaceuticals s.l. - midazolam - epilepsi - neuroleptika - behandling av långvariga, akuta, konvulsiva anfall hos spädbarn, småbarn, barn och ungdomar (från tre månader till under 18 år). buccolam får endast användas av föräldrar till / vårdare där patienten har fått diagnosen att ha epilepsi. för barn mellan tre och sex månaders ålder, behandling bör vara i en sjukhusmiljö där övervakning är möjlig och utrustning för återupplivning finns.

Europeiska unionen - svenska - EMA (European Medicines Agency)

pharmaand gmbh - darifenacinhydrobromid - urinary incontinence, urge; urinary bladder, overactive - urologiska medel, läkemedel för urin frekvens och inkontinens - symtomatisk behandling av trängselinkontinens och / eller ökad urinfrekvens och brådskande frekvens som kan uppstå hos vuxna patienter med överaktiv blåsesyndrom.